Skip to main content

Table 1 Comparison of baseline characteristics of unmatched and matched patients according to the survival status

From: Monocyte-to-lymphocyte ratio is associated with 28-day mortality in patients with acute respiratory distress syndrome: a retrospective study

Variables Original cohort Matched cohort
Survivors (n=183) Non-survivors (n=85) P value Survivors (n=56) Non-survivors (n=56) P value
Age (years) 67 (59–72) 67 (63–73) 0.165 67 (60.25–73) 67 (62–73) 0.730
Male, n (%) 133 (72.7) 59 (69.4) 0.581 39 (69.6) 39 (69.6) 1.000
Smoking, n (%) 60 (32.8) 25 (29.4) 0.581 14 (25) 18 (32.1) 0.557
Alcohol abuse, n (%) 45 (24.6) 18 (21.2) 0.540 10 (17.9) 12 (21.4) 0.815
Hypertension, n (%) 85 (46.4) 31 (36.5) 0.125 22 (39.3) 24 (42.9) 0.851
Diabetes mellitus, n (%) 52 (28.4) 22 (25.9) 0.666 21 (37.5) 17 (30.4) 0.572
Coronary artery disease, n (%) 36 (19.7) 18 (21.2) 0.775 12 (21.4) 13 (23.2) 1.000
Risk factor, n (%)    0.531    0.912
 Pneumonia 167 (91.3) 79 (92.9)   51 (91.1) 51 (91.1)  
 Aspiration 8 (4.4) 2 (2.4)   2 (3.6) 1 (1.7)  
 Sepsis 3 (1.6) 3 (3.5)   2 (3.6) 3 (5.5)  
 Others 5 (2.7) 1 (1.2)   1 (1.7) 1 (1.7)  
Types of infection, n (%)    0.941    0.931
 Bacteria 139 (76%) 64 (75.3%)   49 (87.6) 49 (87.6)  
 Virus 6 (3.3%) 2 (2.4%)   1 (1.7) 1 (1.7)  
 Fungus 24 (13.1) 13 (15.3%)   1 (1.7) 2 (3.6)  
 Unknown 14 (7.6%) 6 (7 %)   5 (9) 4 (7.1)  
PaO2/FiO2 (mmHg) 145 (106–208.18) 131 (85.6–177.03) 0.032 144.64±62.79 145.40 ±58.73 0.948
Categories of ARDS, n (%)    0.015    0.770
 Mild 47 (25.7) 10 (11.8)   12 (21.4) 9 (16.1)  
 Moderate 95 (51.9) 46 (54.1)   27 (48.2) 32 (57.1)  
 Severe 41 (22.4) 29 (34.1)   17 (30.4) 15 (26.8)  
WBC, 109/L 9.8 (7.02–11.84) 9.22 (6–11.46) 0.249 10.44 (8.55–12.15) 9.62 (7.73–11.44) 0.153
Hemoglobin, g/L 111 (96–127) 111 (94.5–126) 0.460 106 (94–126.75) 112 (99–126.75) 0.884
RDW, % 14 (13–15.3) 13.6 (12.85–14.6) 0.175 13.9 (12.75–15.28) 13.45 (12.8–14.55) 0.964
Lactate, mmol/L 2.2 (1.4–3.7) 2.6 (1.55–4.3) 0.082 2.1 (1.3–3.33) 2.6 (1.5–3.73) 0.152
Albumin, g/L 32.9 (28.9–37.7) 32.30 (28.6–37.5) 0.417 32.89±6.98 32.86±5.86 0.979
MLR 0.49 (0.27–0.8) 1 (0.5–1.74) <0.001 0.56 (0.34–0.77) 0.83(0.47–1.68) 0.001
NLR 10.61(4.75–19.42) 14.28 (7.97–23.62) 0.003 13.56 (5.98–25.12) 12.96 (7.18–20.75) 0.613
RDW/albumin, %/g/L 0.43 (0.37–0.51) 0.43 (0.37–0.5) 0.914 0.43 (0.36–0.52) 0.43 (0.36–0.49) 0.660
AST 52.2 (20.5–145.2) 71 (28.7–138.3) 0.317 42.35 (20.1–128.25) 88.05 (36.98–147.9) 0.011
ALT 62 (20–126) 40.3 (21.1–133.3) 0.485 44.6 (16.13–103.75) 43.4 (23.03–139.15) 0.324
Cr, μmol/L 100.7 (60.2–183) 124.9 (62–198.15) 0.357 107 (58.18–188.7) 111.3(60.65-192) 0.695
BUN, mmol/L 13.31 (7–18) 13.55 (9.85–19.25) 0.232 13.09±6.45 13.89±7.28 0.512
APACHE II score 12 (9–16) 15 (10–18) 0.004 14.09±4.50 13.66 ±4.57 0.628
SOFA score 7 (6–9) 8 (7–9) 0.009 8 (7–9) 8 (6.25–9) 0.340
Interventions, n (%)       
 Steroida 121 (66.1) 63 (74.1) 0.189 39 (69.6) 42 (75) 0.690
 Hypoglycemic 56 (30.6) 25 (29.4) 0.844 25 (44.6) 19 (33.9) 0.362
 Alimentotherapy 113 (61.7) 66 (77.6) 0.010 39 (69.6) 42 (75) 0.607
 Albumin infusion 81 (44.3) 56 (66.9) 0.001 36 (64.3) 30 (53.6) 0.286
 Transfusion 50 (27.3) 33 (38.8%) 0.037 19 (33.9) 19(33.9) 1.000
 CRRT 22 (12) 17 (20) 0.085 8 (14.3) 8 (14.3) 1.000
 ECMO 6 (3.3) 5 (5.8) 0.317 1 (1.7) 1 (1.7) 1.000
 Mechanical ventilation 108 (59) 51 (60) 0.879 37 (66.1) 35 (62.5) 0.851
Duration of ventilation 7 (2–13) 8 (3.5–13) 0.479 8.95±7.03 9.05±6.43 0.933
Hospital length of stay 20 (12–26) 17 (11–23) 0.038 19.00±9.81 18.30±8.19 0.662
  1. aSteroid therapy was defined as at least a dose (≥ 0.5mg/kg) of methylprednisolone during hospitalization
  2. ARDS, acute respiratory distress syndrome; WBC, white blood cell; RDW, red cell distribution width; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Cr, creatinine; BUN, blood urea nitrogen; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation